nach oben

Erschienen in:

17.05.2016 | Original Research Article

Combinatorial Study of a Novel Poly (ADP-ribose) Polymerase Inhibitor and an HDAC Inhibitor, SAHA, in Leukemic Cell Lines

verfasst von: Mahesh Hegde, Kempegowda Mantelingu, Monica Pandey, Chottanahalli S. Pavankumar, Kanchugarakoppal S. Rangappa, Sathees C. Raghavan

Erschienen in: Targeted Oncology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Cancer is a multifactorial disease, which makes it difficult to cure. Since more than one defective cellular component is often involved during oncogenesis, combination therapy is gaining prominence in the field of cancer therapeutics.

Objective

The purpose of this study was to investigate the combinatorial effects of a novel PARP inhibitor, P10, and HDAC inhibitor, SAHA, in leukemic cells.

Methods

Combinatorial effects of P10 and SAHA were tested using propidium iodide staining in different leukemic cells. Further, flowcytometry-based assays such as calcein-AM/ethidium homodimer staining, annexin-FITC/PI staining, and JC-1 staining were carried out to elucidate the mechanism of cell death. In addition, cell-cycle analysis, immunocytochemistry studies, and western blotting analysis were conducted to check the combinatorial effect in Nalm6 cells.

Results

Propidium iodide staining showed that P10 in combination with SAHA induced cell death in Nalm6 cells, in which PARP expression and activity is high with a combination index of <0.2. Annexin-FITC/PI staining, JC-1 staining, and other biochemical assays revealed that P10 in combination with SAHA induced apoptosis by causing a change in mitochondrial membrane potential in >65 % cells. Importantly, combinatorial treatment induced S phase arrest in 40-45 % cells due to DNA damage and plausible replicative stress. Finally, we demonstrated that treatment with P10 led to DNA strand breaks, which were further potentiated by SAHA (p < 0.01), leading to activation of apoptosis and increased cell death in PARP-positive leukemic cells.

Conclusions

Our study reveals that coadministration of PARP inhibitor with SAHA could be used as a combination therapy against leukemic cells that possess high levels of intrinsic PARP activity.

Nur mit Berechtigung zugänglich

Chang P, Jacobson MK, Mitchison TJ. Poly(ADP-ribose) is required for spindle assembly and structure. Nature. 2004;432(7017):645–9. doi:10.1038/nature03061.CrossRefPubMed

Chang P, Coughlin M, Mitchison TJ. Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function. Nat Cell Biol. 2005;7(11):1133–9. doi:10.1038/ncb1322.CrossRefPubMed

Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 2008;13:3046–82.CrossRefPubMed

Koh DW, Dawson TM, Dawson VL. Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res. 2005;52(1):5–14. doi:10.1016/j.phrs.2005.02.011.CrossRefPubMed

Malanga M, Althaus FR. The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem Cell Biol. 2005;83(3):354–64. doi:10.1139/o05-038.CrossRefPubMed

Vyas S, Chesarone-Cataldo M, Todorova T, Huang YH, Chang P. A systematic analysis of the PARP protein family identifies new functions critical for cell physiology. Nat Commun. 2013;4:2240. doi:10.1038/ncomms3240.CrossRefPubMedPubMedCentral

Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006;7(7):517–28. doi:10.1038/nrm1963.CrossRefPubMed

Hottiger MO, Hassa PO, Luscher B, Schuler H, Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci. 2010;35(4):208–19. doi:10.1016/j.tibs.2009.12.003.CrossRefPubMed

Yelamos J, Schreiber V, Dantzer F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med. 2008;14(4):169–78. doi:10.1016/j.molmed.2008.02.003.CrossRefPubMed

10.

Ame JC, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, et al. PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem. 1999;274(25):17860–8.CrossRefPubMed

11.

Rulten SL, Fisher AE, Robert I, Zuma MC, Rouleau M, Ju L, et al. PARP-3 and APLF function together to accelerate nonhomologous end-joining. Mol Cell. 2011;41(1):33–45. doi:10.1016/j.molcel.2010.12.006.CrossRefPubMed

12.

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7. doi:10.1038/nature03443.CrossRefPubMed

13.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21. doi:10.1038/nature03445.CrossRefPubMed

14.

Giannini G, Battistuzzi G, Vesci L, Milazzo FM, De Paolis F, Barbarino M, et al. Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold. Bioorg Med Chem Lett. 2014;24(2):462–6. doi:10.1016/j.bmcl.2013.12.048.CrossRefPubMed

15.

Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009;52(2):514–23. doi:10.1021/jm801171j.CrossRefPubMed

16.

Qiu H. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer--letter. Clin Cancer Res. 2014;20(8):2236. doi:10.1158/1078-0432.CCR-13-2679.CrossRefPubMed

17.

Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007;6(3):945–56. doi:10.1158/1535-7163.MCT-06-0552.CrossRefPubMed

18.

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34. doi:10.1056/NEJMoa0900212.CrossRefPubMed

19.

Hegde M, Mantelingu K, Swarup HA, Pavankumar CS, Qamar I, Raghavan SC, et al. Novel PARP inhibitors sensitize human leukemic cells in an endogenous PARP activity dependent manner. RSC Adv. 2016;6(8):6308–19. doi:10.1039/C5RA19150E.CrossRef

20.

Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1(3):194–202. doi:10.1038/35106079.CrossRefPubMed

21.

Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389(6649):349–52. doi:10.1038/38664.CrossRefPubMed

22.

Luong QT, O’Kelly J, Braunstein GD, Hershman JM, Koeffler HP. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res. 2006;12(18):5570–7. doi:10.1158/1078-0432.CCR-06-0367.CrossRefPubMed

23.

Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 2001;13(6):477–83.CrossRefPubMed

24.

Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998;95(6):3003–7.CrossRefPubMedPubMedCentral

25.

Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999;401(6749):188–93. doi:10.1038/43710.CrossRefPubMed

26.

Richon VM, Zhou X, Rifkind RA, Marks PA. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis. 2001;27(1):260–4. doi:10.1006/bcmd.2000.0376.CrossRefPubMed

27.

Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26(9):1351–6. doi:10.1038/sj.onc.1210204.CrossRefPubMed

28.

Chen B, Butte AJ. Network medicine in disease analysis and therapeutics. Clin Pharmacol Ther. 2013;94(6):627–9. doi:10.1038/clpt.2013.181.CrossRefPubMed

29.

Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56–68. doi:10.1038/nrg2918.CrossRefPubMedPubMedCentral

30.

Burkle A, Chen G, Kupper JH, Grube K, Zeller WJ. Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis. 1993;14(4):559–61.CrossRefPubMed

31.

Dungey FA, Loser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys. 2008;72(4):1188–97. doi:10.1016/j.ijrobp.2008.07.031.CrossRefPubMed

32.

Weltin D, Holl V, Hyun JW, Dufour P, Marchal J, Bischoff P. Effect of 6(5H)-phenanthridinone, a poly (ADP-ribose)polymerase inhibitor, and ionizing radiation on the growth of cultured lymphoma cells. Int J Radiat Biol. 1997;72(6):685–92.CrossRefPubMed

33.

Hegde M, Karki SS, Thomas E, Kumar S, Panjamurthy K, Ranganatha SR, et al. Novel levamisole derivative induces extrinsic pathway of apoptosis in cancer cells and inhibits tumor progression in mice. PLoS ONE. 2012;7(9), e43632. doi:10.1371/journal.pone.0043632.CrossRefPubMedPubMedCentral

34.

Kumar S, Gopalakrishnan V, Hegde M, Rana V, Dhepe SS, Ramareddy SA, et al. Synthesis and antiproliferative activity of imidazo[2,1-b][1,3,4]thiadiazole derivatives. Bioorg Med Chem Lett. 2014;24(19):4682–8. doi:10.1016/j.bmcl.2014.08.032.CrossRefPubMed

35.

Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55.CrossRefPubMed

36.

Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–6. doi:10.1158/0008-5472.CAN-09-1947.CrossRefPubMed

37.

Hegde M, Sharath Kumar KS, Thomas E, Ananda H, Raghavan SC, Rangappa KS. A novel benzimidazole derivative binds to the DNA minor groove and induces apoptosis in leukemic cells. RSC Adv. 2015;5(113):93194–208. doi:10.1039/C5RA16605E.CrossRef

38.

Kumar S, Hegde M, Gopalakrishnan V, Renuka VK, Ramareddy SA, De Clercq E, et al. 2-(4-Chlorobenzyl)-6-arylimidazo[2,1-b][1,3,4]thiadiazoles: synthesis, cytotoxic activity and mechanism of action. Eur J Med Chem. 2014;84:687–97. doi:10.1016/j.ejmech.2014.07.054.CrossRefPubMed

39.

Srivastava M, Hegde M, Chiruvella KK, Koroth J, Bhattacharya S, Choudhary B, et al. Sapodilla plum (Achras sapota) induces apoptosis in cancer cell lines and inhibits tumor progression in mice. Sci Rep. 2014;4:6147. doi:10.1038/srep06147.CrossRefPubMedPubMedCentral

40.

Katiyar A, Hegde M, Kumar S, Gopalakrishnan V, Bhatelia KD, Ananthaswamy K, et al. Synthesis and evaluation of the biological activity of N[prime or minute]-[2-oxo-1,2 dihydro-3H-indol-3-ylidene] benzohydrazides as potential anticancer agents. RSC Adv. 2015;5(56):45492–501. doi:10.1039/C5RA01528F.CrossRef

41.

Somasagara RR, Hegde M, Chiruvella KK, Musini A, Choudhary B, Raghavan SC. Extracts of strawberry fruits induce intrinsic pathway of apoptosis in breast cancer cells and inhibits tumor progression in mice. PLoS ONE. 2012;7(10), e47021. doi:10.1371/journal.pone.0047021.CrossRefPubMedPubMedCentral

42.

John F, George J, Vartak SV, Srivastava M, Hassan PA, Aswal VK, et al. Enhanced efficacy of pluronic copolymer micelle encapsulated SCR7 against cancer cell proliferation. Macromol Biosci. 2015;15(4):521–34. doi:10.1002/mabi.201400480.CrossRefPubMed

43.

Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, Hegde M, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. 2012;151(7):1474–87. doi:10.1016/j.cell.2012.11.054.CrossRefPubMed

44.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45. doi:10.1056/NEJMoa033025.CrossRefPubMed

45.

Bullock K, Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist. 2008;13(5):515–25. doi:10.1634/theoncologist.2007-0204.CrossRefPubMed

46.

Wu M, Sirota M, Butte AJ, Chen B. Characteristics of drug combination therapy in oncology by analyzing clinical trial data on ClinicalTrials.gov. Pac Symp Biocomput. 2015:68–79.

47.

Bishop JF, Lowethal R, Joshua D, Matthews JP, Wolf MM, Cooper IA. Etoposide in leukemia. Cancer. 1991;67(1 Suppl):285–91.CrossRefPubMed

48.

Baldan F, Mio C, Allegri L, Puppin C, Russo D, Filetti S, et al. Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line. Int J Endocrinol. 2015;2015:978371. doi:10.1155/2015/978371.CrossRefPubMedPubMedCentral

49.

Chen X, Wong P, Radany EH, Stark JM, Laulier C, Wong JY. Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol Cancer Res. 2012;10(8):1052–64. doi:10.1158/1541-7786.MCR-11-0587.CrossRefPubMed

50.

Chen X, Radany EH, Wong P, Ma S, Wu K, Wang B, et al. Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants. PLoS ONE. 2013;8(12), e84515. doi:10.1371/journal.pone.0084515.CrossRefPubMedPubMedCentral

51.

Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol Oncol. 2014;133(3):599–606. doi:10.1016/j.ygyno.2014.03.007.CrossRefPubMedPubMedCentral

52.

Mao Z, Bozzella M, Seluanov A, Gorbunova V. DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle. 2008;7(18):2902–6.CrossRefPubMedPubMedCentral

Titel: Combinatorial Study of a Novel Poly (ADP-ribose) Polymerase Inhibitor and an HDAC Inhibitor, SAHA, in Leukemic Cell Lines
verfasst von: Mahesh Hegde
Kempegowda Mantelingu
Monica Pandey
Chottanahalli S. Pavankumar
Kanchugarakoppal S. Rangappa
Sathees C. Raghavan
Publikationsdatum: 17.05.2016
Verlag: Springer International Publishing
Erschienen in: Targeted Oncology / Ausgabe 5/2016
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-016-0441-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Combinatorial Study of a Novel Poly (ADP-ribose) Polymerase Inhibitor and an HDAC Inhibitor, SAHA, in Leukemic Cell Lines

Abstract

Background

Objective

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Long-Term Survivor with Intrathecal and Intravenous Trastuzumab Treatment in Metastatic Breast Cancer

Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus

Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment

Overexpression of Ran GTPase Components Regulating Nuclear Export, but not Mitotic Spindle Assembly, Marks Chromosome Instability and Poor Prognosis in Breast Cancer

Ceritinib: a Review in ALK-Positive Advanced NSCLC

Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie